Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.

Becker MA, Hou X, Tienchaianada P, Haines BB, Harrington SC, Weroha SJ, Sathyanarayanan S, Haluska P.

BMC Cancer. 2016 Oct 20;16(1):814.

2.

Molecular and clinical implementations of ovarian cancer mouse avatar models.

Zayed AA, Mandrekar SJ, Haluska P.

Chin Clin Oncol. 2015 Sep;4(3):30. doi: 10.3978/j.issn.2304-3865.2015.04.01. Review.

3.

Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.

Lodhia KA, Tienchaiananda P, Haluska P.

Front Oncol. 2015 Jul 8;5:142. doi: 10.3389/fonc.2015.00142. Review.

4.

Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.

Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P.

PLoS One. 2015 May 11;10(5):e0126867. doi: 10.1371/journal.pone.0126867.

5.

Prioritizing therapeutic targets using patient-derived xenograft models.

Lodhia KA, Hadley AM, Haluska P, Scott CL.

Biochim Biophys Acta. 2015 Apr;1855(2):223-34. doi: 10.1016/j.bbcan.2015.03.002. Review.

6.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760.

7.

A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.

Becker MA, Haluska P Jr, Bale LK, Oxvig C, Conover CA.

Mol Cancer Ther. 2015 Apr;14(4):973-81. doi: 10.1158/1535-7163.MCT-14-0880.

8.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC.

Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533.

9.

Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.

Reid JM, Goetz MP, Buhrow SA, Walden C, Safgren SL, Kuffel MJ, Reinicke KE, Suman V, Haluska P, Hou X, Ames MM.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1271-8. doi: 10.1007/s00280-014-2605-7.

10.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE.

Br J Cancer. 2014 Nov 11;111(10):1932-44. doi: 10.1038/bjc.2014.497.

11.

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

King H, Aleksic T, Haluska P, Macaulay VM.

Cancer Treat Rev. 2014 Oct;40(9):1096-105. doi: 10.1016/j.ctrv.2014.07.004. Review.

12.

Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.

Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P.

Clin Cancer Res. 2014 Sep 15;20(18):4747-57. doi: 10.1158/1078-0432.CCR-14-0114. Erratum in: Clin Cancer Res. 2014 Dec 1;20(23):6224. Huang, Jaiqi [corrected to Huang, Jiaqi].

13.

Patient-derived xenograft models in gynecologic malignancies.

Scott CL, Mackay HJ, Haluska P Jr.

Am Soc Clin Oncol Educ Book. 2014:e258-66. doi: 10.14694/EdBook_AM.2014.34.e258. Review.

14.

North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.

Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL; Alliance for Clinical Trials in Oncology..

Cancer. 2014 Jun 15;120(12):1890-7. doi: 10.1002/cncr.28654.

15.

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P.

Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611.

16.

Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.

Scott CL, Becker MA, Haluska P, Samimi G.

Front Oncol. 2013 Dec 4;3:295. doi: 10.3389/fonc.2013.00295. Review.

17.

Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth.

Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P.

Mol Cancer Ther. 2013 Dec;12(12):2909-16. doi: 10.1158/1535-7163.MCT-13-0547.

18.

Epithelial ovarian cancer experimental models.

Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS.

Oncogene. 2014 Jul 10;33(28):3619-33. doi: 10.1038/onc.2013.321. Review.

19.

Two birds with one stone: octreotide treatment for acromegaly and breast cancer.

Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A.

J Clin Oncol. 2013 Aug 10;31(23):e398-400. doi: 10.1200/JCO.2012.46.6383. No abstract available.

20.

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF.

Breast Cancer Res Treat. 2013 May;139(1):145-53. doi: 10.1007/s10549-013-2528-8.

Items per page

Supplemental Content

Loading ...
Support Center